BIOGEN INC.

(BIIB)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 05-07-2022
212.58 USD   +0.93%
24/06Biogen beëindigt studie naar Alzheimermedicijn Aduhelm over dekkingslimieten
MT
22/06Biogen, Happify Health werken samen om digitale diensten aan te bieden aan Multiple Sclerose patiënten
MT
22/06Biogen en Happify Health werken samen om Multiple Sclerose patiënten te ondersteunen op digitaal platform
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Communiquťs de presse de la sociťtť BIOGEN INC.
01:31The u.s. fda accepts and grants priority review for eisai's biologics license applicati..
PR
22/06Biogen Inc. - European Patent Office Grants Patent Related to TECFIDERA (Dimethyl Fumar..
AQ
22/06Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital..
BU
21/06BIOGEN INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote o..
AQ
21/06European Patent Office Grants Patent Related to TECFIDERAģ (Dimethyl Fumarate)
GL
16/06Biogen Inc. - New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA P..
AQ
15/06BIOGEN : Annual Stockholder Presentation 2022
PU
15/06BIOGEN : Appreciation Statement for Retiring Board Members Nancy Leaming and Brian Posner
PU
15/06New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treate..
GL
15/06New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treate..
AQ
14/06The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities
GL
08/06Biogen And Samsung Bioepis Launch BYOOVIZ (ranibizumab-nuna)
AQ
08/06BIOGEN : Withdrawal from the Jefferies Healthcare Conference
PU
06/06Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar..
AQ
06/06Biogen Inc. - New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Me..
AQ
06/06Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL0181..
GL
06/06Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL0181..
AQ
03/06Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar..
GL
03/06Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar..
AQ
03/06New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benef..
GL
03/06New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benef..
AQ
02/06Biogen and Samsung Bioepis' BYOOVIZ™ (ranibizumab-nuna) Launches in the United St..
AQ
31/05Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor..
AQ
27/05BIOGEN : to Participate in the Jefferies Healthcare Conference
PU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
BU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
GL
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
AQ
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
03/05BIOGEN INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
03/05Change at the top for Biogen after Alzheimer's drug flops
AQ
03/05BIOGEN INC. : Results of Operations and Financial Condition, Change in Directors or Princi..
AQ
03/05BIOGEN : Reports First Quarter 2022 Results
PU
03/05BIOGEN : Q1 2021 Biogen Earnings Presentation
PU
30/04BIOGEN : Statement Regarding Updated ADUHELMģ (aducanumab-avwa) Prescribing Information in..
PU
28/04Samsung Biologics Completes Full Acquisition Of Samsung Bioepis
AQ
22/04BIOGEN : Update on Regulatory Submission for Aducanumab in the European Union
PU
20/04BIOGEN : Completes Sale of Equity Stake in Biosimilar Joint Venture to Samsung Biologics f..
PU
08/04BIOGEN : Statement on the Final National Coverage Determination for Amyloid-Beta Targeting..
PU
05/04BIOGEN : to Report First Quarter 2022 Financial Results May 3, 2022
PU
04/04New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerg..
AQ
30/03Biogen Submits Final Protocol for ADUHELMģ (aducanumab-avwa) Phase 4 ENVISION Trial to ..
AQ
28/03Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9or..
AQ
23/03Eisai Co., Ltd - LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKE..
AQ
22/03Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship t..
AQ
18/03BIOGEN : The National Minority Quality Forum and Biogen Highlight Equitable Access to Rese..
PU
17/03BIOGEN : to Participate in the Stifel 2022 CNS Days
PU
17/03Biogen Announces Peer-Reviewed Publication of ADUHELM Phase 3 EMERGE and ENGAGE Data in..
AQ
17/03Long-Term Phase 3 Data Show ADUHELM Continues to Reduce Underlying Pathologies of Alzhe..
AQ
16/03Biogen Announces Peer-Reviewed Publication of ADUHELMģ Phase 3 EMERGE and ENGAGE Data i..
GL
16/03Biogen Announces Peer-Reviewed Publication of ADUHELMģ Phase 3 EMERGE and ENGAGE Data i..
GL
16/03Long-Term Phase 3 Data Show ADUHELMģ Continues to Reduce Underlying Pathologies of Alzh..
AQ
15/03Eisai - ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMER'S DISEASE TREATMENT COLLABORATI..
AQ
15/03Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments
AQ
14/03Biogen to Present New Research at the International Conference on Alzheimer's and Parki..
AQ
14/03Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
AQ
11/03Biogen to Present New Research at the†International Conference on Alzheimer's and Parki..
AQ
07/03Eisai initiates submission of application data under the prior assessment consultation ..
AQ
04/03BIOGEN INC. COMPANY NEWS : Berger Montague Investigates Securities Fraud Allegations Again..
PR
04/03Eisai initiates submission of application data under the prior assessment consultation ..
PR
24/02Xbrane Biopharma releases Year-end report 2021
AQ
18/02BIOGEN : to Present at the Cowen 42nd Annual Health Care Conference
PU
17/02Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key S..
AQ
17/02Biogen And Xbrane Enter Into Worldwide Commercialization And License Agreement For Cert..
AQ
11/02Biogen Submits Response to the Centers for Medicare and Medicaid Services (CMS) Propose..
AQ
10/02BIOGEN : Submits Response to the Centers for Medicare and Medicaid Services (CMS) Proposed..
PU
08/02Biogen and xbrane announce commercialization and license agreement for proposed biosimi..
AQ
07/02Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimi..
AQ
04/02Biogen reports fourth quarter and full year 2021 results
AQ
03/02BIOGEN INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
03/02Biogen's 2022 outlook leaves investors wanting, shares slip
AQ
03/02BIOGEN : Q4 2021 Biogen Earnings Presentation
PU
03/02BIOGEN : REPORTS FOURTH QUARTER AND FULL YEAR 2021 RESULTS - Form 8-K
PU
03/02BIOGEN : Reports Q4 2021 Earnings
PU
01/02Biogen Exercises Option to Participate in the Development and Commercialization of a La..
AQ
31/01BIOGEN : Announces Nancy Leaming and Brian Posner to Retire from Board of Directors - Form..
PU
1  2  3  4  5  6  7  8  9  10Volgende